MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer

International Journal of Molecular Sciences

Volumn 14, Issue 11, 2013, Pages 21414-21434

  Kalogirou, Charis ^a   Spahn, Martin ^a,b   Krebs, Markus ^a   Joniau, Steven ^c   Lerut, Evelyne ^c   Burger, Maximilian ^a   Scholz, Claus Jürgen ^d   Kneitz, Susanne ^d   Riedmiller, Hubertus ^a   Kneitz, Burkhard ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Biomarker; High risk prostate cancer; microRNA; miR 205; Prognosis

Indexed keywords

MICRORNA 205;

ADVERSE OUTCOME; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VALIDATION PROCESS;

CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886816655     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141121414     Document Type: Article

References (35)

1. Grimm, P.; Billiet, I.; Bostwick, D.; Dicker, A.P.; Frank, S.; Immerzeel, J.; Keyes, M.; Kupelian, P.; Lee, W.R.; Machtens, S.; et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group. BJU Int. 109 Suppl. 2012, 1, 22-29.
2. Bastian, P.J.; Boorjian, S.A.; Bossi, A.; Briganti, A.; Heidenreich, A.; Freedland, S.J.; Montorsi, F.; Roach, M., 3rd; Schroder, F.; van Poppel, H.; et al. High-risk prostate cancer: From definition to contemporary management. Eur. Urol. 2012, 61, 1096-1106.
3. Harisinghani, M.G.; Weissleder, R. Sensitive, noninvasive detection of lymph node metastases. PLoS Med. 2004, 1, e66.
4. Choudhury, A.D.; Eeles, R.; Freedland, S.J.; Isaacs, W.B.; Pomerantz, M.M.; Schalken, J.A.; Tammela, T.L.; Visakorpi, T. The role of genetic markers in the management of prostate cancer. Eur. Urol. 2012, 62, 577-587.
5. Kim, T.; Reitmair, A. Non-coding RNAs: Functional aspects and diagnostic utility in oncology. Int. J. Mol. Sci. 2013, 14, 4934-4968.
6. Du, T.; Zamore, P.D. Microprimer: The biogenesis and function of microRNA. Development 2005, 132, 4645-4652.
7. Meltzer, P.S. Cancer genomics: Small RNAs with big impacts. Nature 2005, 435, 745-746.
8. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
9. Huang, Q.; Gumireddy, K.; Schrier, M.; le Sage, C.; Nagel, R.; Nair, S.; Egan, D.A.; Li, A.; Huang, G.; Klein-Szanto, A.J.; et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 2008, 10, 202-210.
10. Spahn, M.; Kneitz, S.; Scholz, C.J.; Stenger, N.; Rudiger, T.; Strobel, P.; Riedmiller, H.; Kneitz, B. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer 2009, 127, 394-403.
11. Ambs, S.; Prueitt, R.L.; Yi, M.; Hudson, R.S.; Howe, T.M.; Petrocca, F.; Wallace, T.A.; Liu, C.G.; Volinia, S.; Calin, G.A.; et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008, 68, 6162-6170.
12. Porkka, K.P.; Pfeiffer, M.J.; Waltering, K.K.; Vessella, R.L.; Tammela, T.L.; Visakorpi, T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67, 6130-6135.
13. Ozen, M.; Creighton, C.J.; Ozdemir, M.; Ittmann, M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27, 1788-1793.
14. Schaefer, A.; Jung, M.; Mollenkopf, H.J.; Wagner, I.; Stephan, C.; Jentzmik, F.; Miller, K.; Lein, M.; Kristiansen, G.; Jung, K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010, 126, 1166-1176.
15. Qin, A.Y.; Zhang, X.W.; Liu, L.; Yu, J.P.; Li, H.; Wang, S.Z.; Ren, X.B.; Cao, S. MiR-205 in cancer: An angel or a devil? Eur. J. Cell Biol. 2013, 92, 54-60.
16. Greene, S.B.; Herschkowitz, J.I.; Rosen, J.M. The ups and downs of miR-205: Identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol. 2010, 7, 300-304.
17. Hagman, Z.; Haflidadottir, B.S.; Ceder, J.A.; Larne, O.; Bjartell, A.; Lilja, H.; Edsjo, A.; Ceder, Y. MiR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br. J. Cancer 2013, 108, 1668-1676.
18. Majid, S.; Dar, A.A.; Saini, S.; Yamamura, S.; Hirata, H.; Tanaka, Y.; Deng, G.; Dahiya, R. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 2010, 116, 5637-5649.
19. Boll, K.; Reiche, K.; Kasack, K.; Morbt, N.; Kretzschmar, A.K.; Tomm, J.M.; Verhaegh, G.; Schalken, J.; von Bergen, M.; Horn, F.; et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2012, 32, 277-285.
20. Iorio, M.V.; Casalini, P.; Piovan, C.; Di Leva, G.; Merlo, A.; Triulzi, T.; Menard, S.; Croce, C.M.; Tagliabue, E. MicroRNA-205 regulates her3 in human breast cancer. Cancer Res. 2009, 69, 2195-2200.
21. Wu, H.; Zhu, S.; Mo, Y.Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009, 19, 439-448.
22. Dijckmeester, W.A.; Wijnhoven, B.P.; Watson, D.I.; Leong, M.P.; Michael, M.Z.; Mayne, G.C.; Bright, T.; Astill, D.; Hussey, D.J. MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following argon plasma ablation of barrett's esophagus. J. Gastrointest. Surg. 2009, 13, 846-853.
23. Gandellini, P.; Folini, M.; Longoni, N.; Pennati, M.; Binda, M.; Colecchia, M.; Salvioni, R.; Supino, R.; Moretti, R.; Limonta, P.; et al. MiR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase cepsilon. Cancer Res. 2009, 69, 2287-2295.
24. Gregory, P.A.; Bert, A.G.; Paterson, E.L.; Barry, S.C.; Tsykin, A.; Farshid, G.; Vadas, M.A.; Khew-Goodall, Y.; Goodall, G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting zeb1 and sip1. Nat. Cell Biol. 2008, 10, 593-601.
25. Puhr, M.; Hoefer, J.; Schafer, G.; Erb, H.H.; Oh, S.J.; Klocker, H.; Heidegger, I.; Neuwirt, H.; Culig, Z. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am. J. Pathol. 2012, 181, 2188-2201.
26. Tucci, P.; Agostini, M.; Grespi, F.; Markert, E.K.; Terrinoni, A.; Vousden, K.H.; Muller, P.A.; Dotsch, V.; Kehrloesser, S.; Sayan, B.S.; et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl. Acad. Sci. USA 2012, 109, 15312-15317.
27. Hulf, T.; Sibbritt, T.; Wiklund, E.D.; Patterson, K.; Song, J.Z.; Stirzaker, C.; Qu, W.; Nair, S.; Horvath, L.G.; Armstrong, N.J.; et al. Epigenetic-induced repression of microRNA-205 is associated with med1 activation and a poorer prognosis in localized prostate cancer. Oncogene 2013, 32, 2891-2899.
28. Markou, A.; Tsaroucha, E.G.; Kaklamanis, L.; Fotinou, M.; Georgoulias, V.; Lianidou, E.S. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem. 2008, 54, 1696-1704.
29. Fletcher, A.M.; Heaford, A.C.; Trask, D.K. Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific miR-205. Transl. Oncol. 2008, 1, 202-208.
30. Vlietstra, R.J.; van Alewijk, D.C.; Hermans, K.G.; van Steenbrugge, G.J.; Trapman, J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998, 58, 2720-2723.
31. Yu, J.; Peng, H.; Ruan, Q.; Fatima, A.; Getsios, S.; Lavker, R.M. MicroRNA-205 promotes keratinocyte migration via the lipid phosphatase ship2. FASEB J. 2010, 24, 3950-3959.
32. Schubert, M.; Spahn, M.; Kneitz, S.; Scholz, C.J.; Joniau, S.; Stroebel, P.; Kneitz, B. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One 2013, 8, e65064.
33. Ciafre, S.A.; Galardi, S.; Mangiola, A.; Ferracin, M.; Liu, C.G.; Sabatino, G.; Negrini, M.; Maira, G.; Croce, C.M.; Farace, M.G. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 2005, 334, 1351-1358.
34. Baek, D.; Villen, J.; Shin, C.; Camargo, F.D.; Gygi, S.P.; Bartel, D.P. The impact of microRNAs on protein output. Nature 2008, 455, 64-71.
35. Grunewald, T.G.; Kammerer, U.; Winkler, C.; Schindler, D.; Sickmann, A.; Honig, A.; Butt, E. Overexpression of lasp-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br. J. Cancer 2007, 96, 296-305.